<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05036850</url>
  </required_header>
  <id_info>
    <org_study_id>CKPTN2019</org_study_id>
    <nct_id>NCT05036850</nct_id>
  </id_info>
  <brief_title>China Kidney Patient Trials Network</brief_title>
  <acronym>CKPTN</acronym>
  <official_title>China Kidney Patient Trials Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>George (Beijing) Clinical Research Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>George Clinical Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multi-centre, observational cohort study of incident and prevalent&#xD;
      patients diagnosed with a kidney disease in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2031</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>eGFR (estimated Glomerular Filtration Rate)</measure>
    <time_frame>Collected six monthly, up to 5 years</time_frame>
    <description>Routine results</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>Collected six monthly, up to 5 years</time_frame>
    <description>Routine results</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Incident and Prevalent Patients</arm_group_label>
    <description>Incident and prevalent patients diagnosed with a kidney disease at participating centres</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from units that provide a comprehensive nephrology service&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Documented diagnosis of primary kidney disease&#xD;
&#xD;
          2. Regular visits (at least 6 monthly) with a physician at a participating site&#xD;
&#xD;
          3. eGFR &gt; 15 ml/min/1.73 m2&#xD;
&#xD;
          4. â‰¥ 2 years of age&#xD;
&#xD;
          5. Willing and able to sign informed consent&#xD;
&#xD;
          6. Willing to be approached about participation in interventional research studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Life-expectancy of less than 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>FanHan Hsu</last_name>
    <phone>+61 2 8052 4300</phone>
    <email>CKPTN@georgeclinical.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Yuan</last_name>
    <phone>+86 201082800476</phone>
    <email>CKPTN@georgeclinical.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Luyckx VA, Tonelli M, Stanifer JW. The global burden of kidney disease and the sustainable development goals. Bull World Health Organ. 2018 Jun 1;96(6):414-422D. doi: 10.2471/BLT.17.206441. Epub 2018 Apr 20.</citation>
    <PMID>29904224</PMID>
  </reference>
  <reference>
    <citation>Tonelli M, Muntner P, Lloyd A, Manns BJ, Klarenbach S, Pannu N, James MT, Hemmelgarn BR; Alberta Kidney Disease Network. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet. 2012 Sep 1;380(9844):807-14. doi: 10.1016/S0140-6736(12)60572-8. Epub 2012 Jun 19.</citation>
    <PMID>22717317</PMID>
  </reference>
  <reference>
    <citation>Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305. Erratum in: N Engl J Med. 2008;18(4):4.</citation>
    <PMID>15385656</PMID>
  </reference>
  <reference>
    <citation>McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011 Feb;26(2):414-30. doi: 10.1093/ndt/gfq665. Epub 2010 Nov 10. Review.</citation>
    <PMID>21068142</PMID>
  </reference>
  <reference>
    <citation>Strippoli GF, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004 Feb;15(2):411-9. Review.</citation>
    <PMID>14747388</PMID>
  </reference>
  <reference>
    <citation>Perkovic V, Craig JC, Chailimpamontree W, Fox CS, Garcia-Garcia G, Benghanem Gharbi M, Jardine MJ, Okpechi IG, Pannu N, Stengel B, Tuttle KR, Uhlig K, Levey AS. Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney Int Suppl (2011). 2017 Oct;7(2):138-144. doi: 10.1016/j.kisu.2017.07.009. Epub 2017 Sep 20. Review.</citation>
    <PMID>30675428</PMID>
  </reference>
  <reference>
    <citation>de Zeeuw D, Heerspink HJL, Jardine M, Perkovic V. Renal trials in diabetes need a platform: time for a global approach? Lancet Diabetes Endocrinol. 2018 May;6(5):356-358. doi: 10.1016/S2213-8587(17)30263-2. Epub 2017 Aug 7.</citation>
    <PMID>28797748</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 27, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Diabetic Nephropathy</keyword>
  <keyword>Hypertensive Kidney Disease</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>GN</keyword>
  <keyword>Focal Segmental Glomerulosclerosis</keyword>
  <keyword>FSGS</keyword>
  <keyword>Membranous Nephropathy</keyword>
  <keyword>Minimal Change Disease</keyword>
  <keyword>IgA Nephropathy</keyword>
  <keyword>Glomerulonephritis not otherwise specified</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The current plan is that only aggregate data will be shared for research purposes. IPD would only be reviewed in incidental findings and only be discussed with the participant in question.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

